What Is Selank?

Published September 2026 · Patriot Labs Research Team · ~14 min read

An immune peptide, aimed at the brain

Most of the peptides in this catalogue that touch the nervous system come from the nervous system, or from a hormone that speaks to it. Selank is the odd one out: its lineage runs through the immune system. Its four-residue core is tuftsin, a natural peptide released from an antibody molecule, and tuftsin’s classical job has nothing to do with mood or cognition — it stimulates the phagocytic cells that engulf bacteria and debris. Selank is tuftsin made durable, and the interesting part of its story is that a molecule with an immune parentage came to be studied primarily as an anxiolytic, a compound investigated for anxiety-reducing activity in laboratory models.

That dual character — an immune-derived peptide with a behavioural research profile — is the thing to hold onto, because it is the thing most easily lost in casual descriptions. Selank is not simply “an anti-anxiety peptide,” and it is not simply “an immune peptide” either. It is a stabilized analogue of an immunomodulatory fragment that, in animal and Russian clinical research, has been characterized across both domains at once. To place it in the wider family, the site’s overview of what peptides are is the natural starting point, and its survey of cognition- and sleep-related research peptides sets Selank beside the compounds it is most often studied alongside, including its sibling Semax.

The chemistry: seven residues and a proline tail

Selank is a heptapeptide — seven amino acids — and in one-letter code the sequence is TKPRPGP: threonine, lysine, proline, arginine, proline, glycine, proline.¹ Written out in full it is Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues — Thr-Lys-Pro-Arg — are tuftsin, lifted intact; the last three — Pro-Gly-Pro — are the added part, and understanding why they were added is the first thing worth knowing about the molecule.

The peptide carries the molecular formula C₃₃H₅₇N₁₁O₉, an average molecular weight of roughly 751.9 g/mol, and the CAS registry number 129954-34-3.¹ Its most distinctive chemical feature is how basic it is: with a lysine and an arginine in a short chain and no acidic residues to balance them, Selank carries a strong net positive charge at neutral pH, a property that matters when a laboratory thinks about how it dissolves and how it behaves on an analytical column. The Pro-Gly-Pro tail is the design’s central trick, and it is the same trick Semax uses. Short natural peptides are fragile: the body is full of peptidase enzymes that trim amino acids off the ends of a chain, and unmodified tuftsin is broken down almost as soon as it appears. Proline is awkwardly shaped for those enzymes to process, and a Pro-Gly-Pro cap at the C-terminus makes the chain markedly more resistant to that trimming. The result is a peptide short enough to synthesize easily and stable enough to survive being studied — the same stabilization strategy that its sibling Semax uses, and a large part of why both molecules exist at all.

The rest of the sequence is unexotic in the useful sense: a short chain with no unusual residues and no modifications beyond the proline tail. That is exactly why it can be made reliably by standard solid-phase peptide synthesis, and why its identity and purity are straightforward to verify with routine analytical tools. Short, defined, and synthesizable is the combination that makes a peptide practical for laboratory work.

Selank, N-acetyl Selank, and the tuftsin label

Search for this molecule and a few names come back. It is most often described simply as a tuftsin analogue or a synthetic analogue of tuftsin, which is accurate: the tetrapeptide sits at the front of the chain, and the peptide is a member of the broader family sometimes called glyprolines for the proline-glycine motif they share. The precise, unambiguous statement is the sequence itself, TKPRPGP, and a research audience is well served by keeping the sequence in mind rather than the shorthand.

As with Semax, there is a family of acetylated variants that a buyer will encounter. N-acetyl Selank adds an acetyl group to the front of the chain, and N-acetyl Selank amidate adds that acetyl group and also converts the C-terminus to an amide. Both changes are made for the same reason the Pro-Gly-Pro tail exists — to slow enzymatic breakdown still further — and they are genuinely different molecules, with different masses and different catalogue entries. The distinction matters for anyone comparing certificates of analysis: “Selank” and “N-acetyl Selank” are not interchangeable labels, and a vial should be characterized as whichever one it actually is. It is the same lesson the site’s guide to reading a certificate of analysis returns to repeatedly: the name on the label is a claim, and the analytics are what confirm it.

A Soviet-era idea about regulatory peptides

The story begins with tuftsin itself. The tetrapeptide was described in 1970 by the immunologist Victor Najjar and colleagues, who named it after Tufts University where the work was done, and characterized it as a natural phagocytosis-stimulating peptide released from the heavy chain of immunoglobulin G.² That is the parent: an immune activator, well studied in its own right, corresponding to residues 289–292 of the IgG heavy chain. What tuftsin lacked, as a research tool, was durability; it was cleared and degraded too fast to work with easily.

The stabilization and the behavioural turn came out of the Soviet, then Russian, research tradition that took regulatory peptides — short peptides that modulate the nervous and immune systems — far more seriously than most Western programmes did at the time. That work is associated with the physiologist Ivan Ashmarin, and Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, in collaboration with the V. V. Zakusov (Zakusov) Institute of Pharmacology.³ It is the same laboratory and the same national programme that produced Semax, and the two molecules share not only a birthplace but a design philosophy: take a natural short peptide with a known activity, append the Pro-Gly-Pro tail to keep it intact, and study the durable analogue that results. In Selank’s case the natural starting peptide was tuftsin, and the durable analogue turned out to have a research profile centred on anxiety and immune signalling. The broader story of how these Russian regulatory peptides came to exist is one reason the compound is studied so often alongside Epithalon, DSIP and Semax, all products of the same research culture.

The pathways the studies point to

What Selank is studied to do, and how, comes mainly from cell and animal work, and the literature describes several threads at once rather than a single clean mechanism. The behavioural interest is in anxiolytic-like activity, and the pathways most often invoked to explain it are the classical inhibitory and monoamine systems of the brain. Studies have reported that Selank influences the GABAergic system, altering the expression of genes that encode subunits of the GABA-A receptor in regions such as the hippocampus and prefrontal cortex, and that it shifts serotonin metabolism, with reported changes in serotonin turnover in those same regions.⁴ Effects on dopamine and noradrenaline handling under stress conditions have also been described. Because GABA and serotonin are the systems most conventional anxiolytics act on, this is the axis around which much of the behavioural Selank literature is organized.

A second, well-documented thread connects Selank back to its parent’s biology. Like tuftsin, Selank has been reported to have immunomodulatory activity — modulating cytokine expression, including interleukin-6 and interferon-gamma, and influencing the balance of immune signalling in experimental models.⁵ A third thread, shared with Semax, concerns the enkephalins: Selank has been reported to inhibit the enzymes that degrade these endogenous opioid peptides — including aminopeptidase and dipeptidyl peptidase activity — which would tend to raise and prolong enkephalin levels, a property studied as one possible contributor to its behavioural profile. Some studies also describe effects on the expression of brain-derived neurotrophic factor (BDNF), linking Selank loosely to the neurotrophic story that dominates the Semax literature, though the connection is less central here.

An honest account has to note the same gap that runs under Semax. Despite a real body of preclinical work, the precise first molecular target of Selank — the single receptor it binds to initiate its cascade, if one such receptor exists — has not been definitively established; reviews describe its mechanism as multifactorial and still incompletely understood. It is a compound whose downstream fingerprint (the GABA and serotonin shifts, the cytokine changes, the enkephalin effect) is far better documented than its first point of contact. For readers placing this beside other compounds the catalogue carries, that makes Selank a useful contrast: where a growth-hormone secretagogue such as CJC-1295 has a clearly defined receptor, Selank is a peptide characterized mostly by the range of systems it appears to touch rather than by a single mechanism.

The research record

Selank sits in the same unusual place its sibling does: more heavily studied than most research peptides, but with almost all of that study concentrated inside one national research system. The preclinical base is genuine and peer-reviewed — the GABA and serotonin work, the immunomodulatory studies, the enkephalin findings, and the pharmacokinetic work on the stability conferred by the Pro-Gly-Pro tail. On top of that base, Russian investigators ran human clinical studies; the most cited compared Selank against a benzodiazepine comparator in the setting of generalized anxiety disorder and neurasthenia, and it is on the strength of that clinical development that Selank became a registered medicine in Russia.⁶ That is more clinical investigation than the great majority of research peptides ever accumulate.

The caveat that has to travel with that record is its concentration and its reach. Much of the clinical literature is Russian-language, was conducted within a single regulatory system, and has not been reproduced in the large, independent, multi-country trials that Western drug approval demands. A deep literature is not the same thing as a globally validated one, and the two should not be conflated. The table below summarizes what the record establishes and where its edges are.

Registered in Russia, absent from the US list

Selank has the same lopsided regulatory profile as its sibling, and laying it out plainly is the clearest way to read the molecule honestly. In Russia, Selank is an approved medicine, sold as an intranasal anxiolytic under a national marketing authorization. That is a real regulatory status, but it exists inside one country’s system and does not transfer. In the United States and most of the world, Selank has never been approved as a drug, has not been evaluated by the FDA for safety or efficacy, and is not a marketed medicine. Those two facts sit side by side and are both true; neither cancels the other, and neither describes what research-grade Selank does for any person.

There is one point where Selank’s recent story and Semax’s diverge, and it is worth stating precisely because it is easy to blur the two together. Peptides sold and used outside the approved-drug system have drawn growing FDA attention, and on July 23–24, 2026 the agency’s Pharmacy Compounding Advisory Committee met to review a slate of seven peptides as candidates for the 503A bulk drug substances list that governs what licensed pharmacies may compound. Those seven were BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Epitalon, and Semax.⁷ Selank was not on that list. Its sibling Semax was reviewed and recommended for inclusion by an 8–5–1 vote; Selank was not part of the review at all. Two things about that follow. First, a Pharmacy Compounding Advisory Committee recommendation is advisory only even for the peptides it covered — the committee does not make law and does not issue approvals. Second, the entire question in that room concerned the compounding-pharmacy pathway — whether pharmacists could prepare a substance for patients — which is a separate regulatory world from the sale of a compound as a research chemical, and one that did not involve Selank regardless.

None of that changes the footing on which a research supplier operates. Whatever a compound’s regulatory trajectory, research-grade Selank is laboratory material, sold for in-vitro research use only, and the current attention on the category is a reason to be more precise about that framing, not less. The site’s guide to how peptides differ from drugs and biologics covers why these categories are drawn where they are, and why a research chemical, a compounded drug, and an approved medicine are three different things even when the molecule is the same.

Bench practice: characterizing the peptide

Selank is supplied as a lyophilised (freeze-dried) solid, and the analytical questions a laboratory should be able to answer about a vial follow directly from the chemistry. Two properties define the target: the correct seven-residue sequence, and the intact state of that sequence. A credible certificate of analysis should let a buyer confirm both.

Identity is established by mass spectrometry: the measured mass should match the expected value for the peptide, near 751.9 for the free base. Purity is established by reversed-phase HPLC, which separates the intended molecule from synthesis-related impurities such as deletion sequences and truncated chains — the incomplete peptides that arise when a residue fails to couple during synthesis. Selank’s strongly basic character, from its lysine and arginine, is relevant to how it is handled on those columns and in solution, and it is part of why the counter-ion the peptide is paired with is worth noting on a certificate. Beyond identity and purity, a thorough COA reports net peptide content (how much of the vial’s mass is actually peptide rather than water and counter-ions), the counter-ion itself (commonly acetate or trifluoroacetate), and endotoxin levels where that matters — the last point carrying extra weight for a molecule with an immunomodulatory research profile, since endotoxin is itself an immune stimulant that could confound immunological work.

Stability follows the general rules for the class. As a dry, lyophilised solid kept cold and protected from light and moisture, the peptide is comparatively stable; once reconstituted it is far more vulnerable, and protection from repeated freeze-thaw cycles and from microbial contamination becomes the practical concern. The site’s storage guide and its account of how peptides degrade cover the practical handling; none of that is a use instruction, only the analytical hygiene that lets a laboratory trust that what is in the vial matches the label. Because Selank is a peptide, it also shares the class’s basic constraint: short peptides are broken down in the digestive tract, which is why the research literature relies on non-oral routes — the intranasal route features prominently in the Selank work — a limitation the peptide-versus-drug explainer unpacks.

What the evidence does not establish

Selank attracts more claims than its evidence supports, and the corrective is to state the boundaries directly. The preclinical and mechanistic work — the GABA and serotonin findings, the immunomodulatory effects, the enkephalin story — is real and peer-reviewed, but it describes what the peptide does in cells and in animal models and in studies conducted largely within one national research system. It does not amount to an independently validated, globally reproduced demonstration of any effect in people, and it says nothing about outcomes for any individual. The registered medical status in Russia is a fact about that country’s regulatory system, not a universal endorsement.

The popular framing of Selank as a ready-made “anti-anxiety peptide” or “natural nootropic” is exactly the kind of shorthand a research audience should hold at arm’s length: it collapses a genuinely interesting but incomplete record — a multi-system preclinical literature, an unresolved primary mechanism, and a clinical history confined to one regulatory system — into a slogan the evidence has not earned. For placing the compound against its nearest research relatives, the Semax versus Selank comparison and the broader survey of cognition- and sleep-related research peptides are the honest reference points.

The honest summary is that Selank is a chemically well-defined research peptide with an unusual immune-to-brain lineage, a multifactorial mechanism, and a regulatory history confined to one country — and that this combination is exactly what makes it a legitimate subject for laboratory investigation, and exactly why it belongs in a research setting and nowhere else.

Frequently asked questions

Is Selank the same thing as tuftsin?

No. Selank is a synthetic seven-amino-acid peptide built from tuftsin, not tuftsin itself. Tuftsin is a natural four-residue peptide, Thr-Lys-Pro-Arg, that corresponds to residues 289 to 292 of the heavy chain of immunoglobulin G and is classically described as a stimulator of phagocytosis. Selank is that tetrapeptide with an added Pro-Gly-Pro tail appended to the end. The added tail is the whole point of the design: an unmodified tuftsin fragment is broken down by peptidase enzymes very quickly, and the Pro-Gly-Pro cap makes the chain far more resistant to that trimming. So Selank is best described as a stabilized synthetic analogue of tuftsin, engineered to last long enough to be studied.

Is Selank approved by the FDA?

No. Selank has never been approved by the FDA as a drug for any indication, and it has not been evaluated or marketed as a medicine in the United States. It is a registered pharmaceutical only in Russia and a few neighbouring states, where it is sold as an intranasal anxiolytic. In the US it exists as a research chemical, and research-grade Selank supplied by Patriot Labs is laboratory material sold for in-vitro research use only.

Was Selank part of the July 2026 FDA peptide review?

No. On July 23 and 24, 2026 the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides as candidates for the 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Epitalon, and Semax. Selank was not among them, even though its sibling Semax was. The distinction is worth keeping straight: the compounding review concerned whether licensed pharmacies could prepare those specific substances for patients, and it did not touch Selank at all. Whatever its outcome, it changes nothing about the footing on which research-grade Selank is offered, which is laboratory use only.

How is Selank related to Semax?

They are siblings from the same research programme rather than the same molecule. Both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both use the same trick for stability: appending a Pro-Gly-Pro tail that resists the enzymes which would otherwise degrade a short peptide quickly. But their parent sequences are completely different. Selank derives from the immune peptide tuftsin and is studied mainly in anxiolytic and immunomodulatory contexts, while Semax derives from a fragment of the hormone ACTH and is studied mainly in neurotrophic ones. The site’s Semax versus Selank comparison walks through the distinction in detail.

Is Selank intended for human use?

No. Selank supplied by Patriot Labs is sold strictly for in-vitro research and laboratory use only. It is not for human or veterinary consumption, and nothing in this guide describes how to administer it. The registered medicine that exists in Russia is a separate, nationally regulated product; research-grade Selank is a laboratory material characterized for identity and purity, and that is the only footing on which it is offered here. For the practical side of sourcing verified material, see the guide on storing research peptides and the COA explainer.

References

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.